Phase 1 N=24 Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®
Glaucoma
Primary: Number of Adverse Events — 28; 31 adverse events — p=0.706
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Glaucoma
Primary: Number of Participants With Adverse Events — 10; 11 Participants — p=1.000
Phase 1 N=35 The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)
Postherpetic Neuralgia
Primary: Change From Baseline in Pain Intensity at Week 4 of Each Treatment Period — -1.776; -1.263 Score on a scale — p=0.075
Phase 1 N=18 To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
HIV Infections
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time of Dose Extrapolated to Infinity (AUC[0-inf]) in Part 1 of DTG — 59.761; 101.125; 77.742 Hours*microgram…
Phase 1 N=35 A Study of Lasmiditan in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan — 368; 304 Nanograms Per Millilitre (ng/mL)
Phase 1 N=12 Investigation of the Safety of Intranasal Glulisine in Down Syndrome
Down Syndrome
Primary: Safety Measured by Adverse Events — 0; 0 Participants
Phase 1 N=37 To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers
Tobacco Use Disorder
Primary: Assessment of Bioequivalence of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Area Under the Plasma Concentration Versus Time Curve From Time Zero to…
Phase 1 N=170 PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Advanced Melanoma · Metastatic Melanoma
Primary: Median Change From Baseline to Week 7, of Interferon (IFN) and Interferon Gamma (IFN-gamma) Inducible Factors — 0.0130; 0.0320; 0.2310; 0.1600 pg/mL
Phase 1 N=16 A Study of Lasmiditan in Participants With Migraine
Migraine Disorders
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Lasmiditan in Each Period — 233; 227 nanogram per milliliter (ng/mL)
Phase 1 N=16 Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
Migraine
Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)
Phase 1 N=44 A Study of Lasmiditan and Propranolol in Healthy Participants
Healthy
Primary: Change From Baseline (Day 8) in Mean Hourly Heart Rate Following Propranolol Administered Alone and When Coadministered With Lasmiditan — 59.7; 54.2 beats per minute (bpm)
Phase 1 N=42 Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Migraine
Primary: Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Systolic Blood Pressure — 0.6; -2.3; -0.1 millimeters of mercury (mmHg)
Phase 1 N=15 An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
Parkinson Disease
Primary: Safety and Tolerability Based on the Safety Variables (Adverse Events, Clinical Safety Laboratory Tests, Vital Signs, Weight, and ECG) — 0; 0; 2; 7 Participants
Phase 1 N=36 A Study of Lasmiditan in Healthy Elderly Participants
Healthy
Primary: Pharmacodynamics: Change From Baseline in Peak Hourly Mean Values of Systolic Blood Pressure (SBP) — 15.79; 15.50; 17.14 millimeters of mercury (mmHg) — p=<0.0001
Phase 1 N=27 A Study of Lasmiditan in Healthy Japanese and Caucasian Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants